Antag Therapeutics' First-in-Class GIPR Antagonist AT7687 Shows Promising Phase 1 Results and Preclinical Combination Data at ADA 2026
核心洞察
Antag Therapeutics (搜索) presented positive Phase 1 results for AT7687, a first-in-class GIP receptor antagonist, at the 2026 ADA Scientific Sessions, demonstrating favorable tolerability and suitability for once-weekly subcutaneous dosing.
In preclinical studies, combining AT7687 with cagrilintide achieved a 12.2% body weight reduction versus 7.8% with cagrilintide alone in obese insulin-resistant non-human primates over 42 days.
The combination therapy improved insulin sensitivity with an 18.9% increase in glucose disappearance rate, compared to a 1.3% decline with cagrilintide monotherapy.
Antag Therapeutics (搜索) has unveiled positive Phase 1 clinical data for AT7687, a first-in-class glucose-dependent insulinotropic polypeptide receptor (GIPR (搜索)) antagonist, at the 2026 Scientific Sessions of the American Diabetes Association (ADA) in New Orleans. The findings, presented on June 7, position AT7687 as a potentially differentiated therapeutic for obesity (搜索) and cardiometabolic disease, with the company now preparing to advance the candidate into Phase 2a development by mid-2026.
"These data strengthen the growing body of evidence supporting AT7687 as a differentiated therapeutic approach and continue to reinforce our belief that GIP receptor antagonism has the potential to support next generation treatment paradigms for obesity (搜索) and cardiometabolic disease," said Philip Just Larsen, Chief Executive Officer of Antag Therapeutics (搜索).
Phase 1 Results Support Once-Weekly Dosing
The first-in-human study, presented in an oral session by Chief Medical Officer Richard Nkulikiyinka, demonstrated that AT7687 was well-tolerated and suitable for once-weekly subcutaneous injection in people living with obesity (搜索). The translational consistency of the pharmacodynamic and tolerability findings has bolstered the company's confidence in the molecule's differentiated profile.
"The translational consistency of the pharmacodynamic and tolerability findings in the Phase 1 study gives us increasing confidence in the differentiated profile of AT7687," said Nkulikiyinka. He further emphasized that the favorable gastrointestinal tolerability profile and the absence of a requirement for titration make AT7687 "a promising profile for potential clinical use both as a monotherapy and in combination with other treatments."
Preclinical Combination Data with Cagrilintide
In a separate poster presentation, Antag shared new preclinical findings evaluating AT7687 in combination with cagrilintide, a dual amylin and calcitonin receptor agonist, in obese insulin-resistant non-human primates (NHPs) maintained on a high-fat diet.
After a 42-day treatment period, the combination of AT7687 and cagrilintide achieved a 12.2% reduction in body weight from baseline, compared with a 7.8% reduction observed with cagrilintide alone. This superior efficacy was accompanied by significant improvements in insulin sensitivity: the combination increased glucose disappearance rate by 18.9%, whereas cagrilintide monotherapy was associated with a 1.3% decline.
The combination also produced the largest reduction in body fat percentage among the treatment groups. Notably, cumulative energy intake was similar between NHPs receiving combination therapy and those treated with cagrilintide alone, suggesting that the enhanced weight loss observed with AT7687 may not be explained solely by appetite suppression.
"The latest, compelling preclinical efficacy data in combination with cagrilintide build on those already previously reported with liraglutide, supporting further investigation of the potential for GIPR (搜索) antagonism to deliver clinically meaningful metabolic benefits to people living with obesity (搜索)," Nkulikiyinka added.
A Mechanistically Distinct Approach
AT7687 is based on decades of research by GLP-1 pioneer Professor Jens Juul Holst and is specifically designed to target and deactivate the GIP receptor, a genetically validated pathway implicated in fat storage, insulin resistance (搜索), and metabolic dysfunction. The peptide has been engineered for straightforward and versatile formulation properties, enabling development as both a monotherapy and a co-formulation with other obesity (搜索) therapies.
Larsen underscored the company's vision for personalized obesity (搜索) care: "Obesity is too complex to be addressed by a one-size-fits-all therapeutic approach. The future lies in flexible, personalized combination therapies that can deliver meaningful efficacy without compromising tolerability or long-term health outcomes, and we believe AT7687 has the potential to become a foundational combination therapy for next-generation obesity treatment."
Corporate Momentum and Next Steps
Antag Therapeutics (搜索) has raised €80 million in a Series A financing led by Versant Ventures (搜索), with participation from Novo Holdings (搜索), SR One, Dawn Biopharma, Pictet, Longview Ventures, and the Export and Investment Fund of Denmark (EIFO). The company recently appointed Philip Just Larsen as CEO in May 2026; Larsen brings more than 20 years of R&D leadership experience from senior roles at Eli Lilly, Novo Nordisk, Bayer, AstraZeneca, and Sanofi, including leadership of the dual incretin agonist programs that contributed to the development of tirzepatide and mazdutide.
The Phase 2a study of AT7687 is expected to commence in mid-2026, marking the next critical step in evaluating this first-in-class GIPR (搜索) antagonist for obesity (搜索) and related metabolic conditions.